Aethlon Medical (NasdaqCM:AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Aeolus Pharmaceuticals, Inc (OTC:AOLS) is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.
Aethlon Medical, Inc. (NasdaqCM: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.
Alexium International Group (ASX:AJX.AX) is engaged in developing and licensing its intellectual property, Reactive Surface Treatment (RST) technology. Alexium is focused on developing the RST technology for a range of military and commercial applications. Alexium's Reactive Surface Treatment (RST) is a technology for nanoscopic coatings that combines advanced materials chemistry with a processing step. Alexium's Reactive Surface Treatment (RST) uses cold microwave energy to direct a precursor's polymerization onto a substrate's surface. Its technology is used in textiles, air/fluid filtration, industrial coatings, composite fibers, leather, glass/lens surface treatment, bulk chemicals and thin films. BIODEFENSE: Responding to specific military and first responder needs, Alexium developed the Cleanshell® chemistry to offer a new generation of liquid repellency protection in chemical and biological threat scenarios. Cleanshell® CB is an advanced repellency treatment, optimized for chemical and biological protection. Cleanshell® CB has been optimized to provide excellent water and oil repellency, but has also dramatically increased the repellency of Chemical Warfare Agent (CWA) simulants. Cleanshell® CB offers days of protection versus minutes for conventional fluorocarbon repellency finishes.
American Science and Engineering, Inc (NasdaqGS: ASEI) is a leading worldwide supplier of innovative X-ray inspection systems. With over 50 years of experience in developing advanced X-ray security systems, the Company's product line utilizes a combination of technologies, including patented Z Backscatter™ technology, Radioactive Threat Detection (RTD), high energy transmission and dual energy transmission X-ray. These technologies offer superior X-ray threat detection for plastic explosives, plastic weapons, liquid explosives, dirty bombs and nuclear devices. AS&E's complete range of products include cargo inspection systems for port and border security baggage screening systems for facility and aviation security, and personnel and passenger screening systems. AS&E® systems protect high-threat facilities and help combat terrorism, trade fraud, drug smuggling, weapon smuggling, illegal immigration, and people smuggling.
BRUKER Corporation (NasdaqGS: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. CBRN (Chemical, biological, radiological, and nuclear defense): The CBRNE threats facing Armed Forces, Emergency and Security Services across the globe are complex. Simple and reliable solutions are required in order to provide protection and fast, effective response. As the market leader in CBRNE for over 20 years, Bruker understand the threat and needs of those operating against it. Our trusted equipment and software is installed around the world providing unrivalled protection. Our equipment is always easy to use and enables full spectrum Detection, Identification and Monitoring utilising state of the art technology.
Cepheid (NasdaqGS: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. BIOTHREATS: The Cepheid GeneXpert® System makes biothreat agent detection possible in minutes - all from unprepared samples. This easy-to-use, automated and highly accurate real-time PCR instrument combines the ingenuity of more than 30 patents into a sophisticated genetic tool for first responders. A patented, disposable, cartridge test for anthrax is available now, and can be performed on-site - delivering critical answers in critical situations.
Cleveland BioLabs, Inc. (NasdaqCM:CBLI) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. BIODEFENSE:Entolimod (CBLB502) Biodefense
Dynasil Corporation of America (NasdaqGM:DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets. Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing.
Electronic Sensor Technology (OTC:ESNR) develops, manufactures, and sells electronic devices used for vapor analysis. The company offers zNose, an electronic nose designed for various industry applications, which can detect odors and chemical vapors produced by explosives, chemicals, and biological weapons, as well as used for identifying hazardous industrial materials, improvised explosives, and flammable materials. Its product is used in the homeland security, chemical and petrochemical, environmental, life science, and food and beverage industries. The company also provides spare parts, such as columns, saw detectors, and traps; and accessories, including rugged shipping case, battery assemblies, battery chargers, DC/AC inverters, desorbers, heaters, remote samplers, sample injectors, system controllers, user tool kits, and water traps, as well as support and validation services. Electronic Sensor Technology offers its products through online store.
Emergent BioSolutions, Inc. (NYSE:EBS) is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company provides the world's only FDA-licensed anthrax vaccine to protect against anthrax disease, BioThrax®.
Epistem Holdings plc (LSE:EHP.L) is a biotechnology and medicine company commercializing its expertise in epithelial stem cells and infectious disease. The Company develops therapeutics, biomarkers and diagnostic products alongside providing preclinical research services for drug development companies. The Company operates in three divisions: Preclinicial Research Services, Personalised Medicine and Novel Therapies. Preclinical Research Services provides preclinical testing services. Personalised Medicine specializes in molecular measures of biological effect and point of care molecular diagnostic testing. Novel Therapies is discovering key regulators of epithelial stem cells. Its subsidiaries include Epistem Limited, Epistem SIP Trustees Limited, Visible Genomics Limited and Epistem Inc. BIODEFENSE: Epistem's expertise and history in radiation biology has been applied to the evaluation of potential mitigators of Acute Radiation Syndrome (ARS) to aid the development of medical countermeasures. Epistem is a member of the USA's National Institute of Allergy and Infectious Disease (NIAID) funded Medical Countermeasures against Radiological Threats (MCART) consortium. MCART was set up as a result of Project Bioshield which aims to protect the USA against weapons of mass destruction. Epistem has over 5 years of experience in the evaluation of ARS mitigators for NIAID. Models are provided with variable levels of bone marrow shielding and types of medical management to mimic a variety of radiation exposures and clinical support measures.
Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® DNA immunotherapies, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.
Landauer Inc. (NYSE:LDR) is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, the leading domestic provider of outsourced medical physics services, as well as a provider of high quality medical accessories used in radiology, radiation therapy, and image guided surgery procedures. For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees. Landauer's services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings. The Company provides its dosimetry services to approximately 1.8 million individuals globally. As the global leader in radiation science and services, we offer scalable radiation dosimetry programs for managing public safety, including local and national governments, emergency response units, military and defense.
Luminex Corporation (NasdaqGS: LMNX) is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety.
NanoLogix, Inc. (OTC: NNLX) is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
Novavax Inc. (NasdaqGS:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates. In addition, the company is developing its vaccine candidates for worldwide commercialization including an advanced seasonal and pandemic influenza vaccine development contract with the U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)and a research collaboration with the U.S. Department of Homeland Security to develop a virus-like particle (VLP)vaccine countermeasure to protect the United States from foot-and-mouth disease.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Sequencing technology, the Company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. Currently, our focus is on applications for clinical, basic and agricultural research, with potential uses in molecular diagnostics, drug discovery and development, food safety, forensics, biosecurity and biofuels.
Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The Company's lead product candidate, omadacycline, is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications of ABSSSI, CABP, uUTI and cUTI. Paratek has completed Phase 3 development activities for omadacycline in CABP and ABSSSI and has initiated its New Drug Application to the U.S. FDA in the United States. Paratek has licensed rights for omadacycline to Zai Lab for the greater China region, and retains all remaining global rights. Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax. Paratek's second Phase 3 product candidate, Seysara™ (sarecycline), is being developed by Allergan in the U.S. as a new once-daily oral therapy for the treatment of acne. Allergan has completed Phase 3 development activities for Seysara and its new drug application was accepted for review by the U.S. Food and Drug Administration in December 2017. Paratek retains all ex-U.S. rights to Seysara.
PharmAthene, Inc. (NYSE MKT:PIP) is a biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. PharmAthene's current biodefense portfolio includes the following product candidates: SparVax® - a next generation recombinant protective antigen (rPA) anthrax vaccine; rBChE bioscavenger - a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides; Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection.
PositiveID Corporation (OTC:PSID) is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples.
Pressure BioSciences, Inc. (OTC: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Response Biomedical Corporation (TSX:RBM.TO; OTC:RPBIF) develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.
Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. We are developing AVI-7288 for the treatment of Marburg virus infection under a contract with the U.S. Department of Defense managed by the Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office. Marburg hemorrhagic fever is a severe and often fatal disease endemic to Africa. Marburg is classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention, and has been designated as a material threat to national security and public health by the U.S. Department of Homeland Security.
SIGA Technologies (NasdaqGM:SIGA) is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is Arestvyr, (TM) (tecovirimat), also known as ST-246(R), an orally administered antiviral drug that targets orthopoxviruses. While Arestvyr is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.
Soligenix, Inc. (OTC:SNGX) is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a BARDA contract award valued up to $26.3 million and a NIAID contract award valued up to $6.4 million. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in a canine model of GI ARS funded by the NIAID. Additionally, Soligenix has an exclusive worldwide collaboration with Intrexon Corporation (XON) focused on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need.
STERIS Corporation (NYSE:STE) is a global leader in infection prevention, contamination control, surgical and critical care technologies, and more. STERIS's Defense and Industrial Group is able to provide a suite of solutions to meet most chemical and biological decontamination needs. The suite includes low logistics chemistries that can be mixed at point and time of use, multi-purpose wipes that meet the daily personal hygiene needs of the warfighter in the field (wipe away and partially neutralize chemical/biological agents), and gaseous decontamination systems for sensitive equipment, vehicles (land, sea and air), and interior spaces of building and shelters.
TapImmune Inc. (OTC:TPIV) is a clinical-stage immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. The Company is also exploiting the emerging field of vaccinomics for the development of vaccines applicable to a broad patient population. TapImmune's immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.
Our site does not give specific recommendations and encourages investors to complete their own due diligence. Our lists are compiled from internal and external research sources. Our lists are to be used only as a partial source of due diligence.